Literature DB >> 15665562

[Indications and limitations of endoscopic mucosal resection in gastric cancer].

Joo Young Cho1.   

Abstract

Endoscopic mucosal resection (EMR) has come to play an increasingly important role in treatment of early cancer in gastrointestinal tract. Recent advances in EMR are very remarkable. These allow minimally invasive treatment of diseases that would otherwise require major surgery. The most important factors of EMR are accuracy and safety. Further improvement in both staging and resection technologies, as well as safety and short procedure time will ultimately conspire to make this an even more effective tool in the management of early cancer in gastrointestinal tract. EMR must prove to be safe for the majority of patients when performed by competent endoscopist. The new techniques will continue to solve the limitations of endoscopic treatment and its use will also continue to expand increasingly. Also, further studies are required to refine and standardize EMR. As EMR technology becomes more complex, necessitating the use of multiple accessories simultaneously, technical ease may be enhanced by simple adjunct devices. The future of EMR depends on extending its boundaries safely in a controlled setting of prospective clinical trials. I believe that current EMR techniques and devices are only the beginning of a new age in therapeutic endoscopy, the age of minimal invasive endosurgery, the next frontier.

Entities:  

Mesh:

Year:  2005        PMID: 15665562

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  2 in total

1.  Stretching Causes Extensive Changes of Gastric Submucosa: Is It Acceptable to Define 500 microm as the Safe Margin?

Authors:  Sanghoon Park; Hoon Jai Chun; Yong Dae Kwon; Bora Keum; Yeon Seok Seo; Yong Sik Kim; Yoon-Tae Jeen; Soon Ho Um; Chang Duck Kim; Ho Sang Ryu; Ji Hye Lee; Yang-Seok Chae
Journal:  Gut Liver       Date:  2008-12-31       Impact factor: 4.519

2.  Efficacy and safety of endoscopic submucosal dissection for early gastric cancer in patients with comorbid diseases.

Authors:  Beom Jin Kim; Tae Hoon Chang; Jae J Kim; Byung-Hoon Min; Jun Haeng Lee; Hee Jung Son; Poong-Lyul Rhee; Jong Chul Rhee; Kyung Mee Kim; Chul Keun Park
Journal:  Gut Liver       Date:  2010-06-16       Impact factor: 4.519

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.